CRISPR Technology Licensing
Our proprietary CRISPR technologies enable precise genome editing and targeted cell depletion across diverse organisms, helping you streamline development and accelerate innovation.
Whether you are working with bacteria, yeast, fungi, plants, or animal cells, our patented nucleases can help you achieve precise genetic modifications or targeted cell depletion while reducing development time and complexity.
Overcoming challenging bottlenecks in microbial strain development
Do you need a solution tailored to a specific microorganism? Benefit from our more than 30 years of experience in microbiology and genetic engineering. We help to overcome challenging bottlenecks in microbial strain development, from standard bacteria to non-conventional yeasts and fungi.
CRISPR-BMC for precise genome editing across diverse organisms
Gain easy access to our proprietary CRISPR-BMC technology and expand your genome editing capabilities with licensed access to our patented technology.
BMC® (BRAIN Metagenome Cas) nucleases are metagenomic enzymes available for multiple classes of microorganisms, as well as for plant and animal cell lines. This technology is protected by a granted European substance patent (EP 4 301 852 B1), which provides legal certainty for commercial applications.
CRISPR-BMC uses guide-RNA-directed nucleases to introduce targeted DNA breaks for precise, marker-free genome editing.
Adapt CRISPR-BMC to your preferred production organism
Are you working with a challenging strain or non-model organism? Our experts can help you adapt the CRISPR-BMC technology to your specific application. We have extensive experience with:
- Gram-positive bacteria
- Gram-negative bacteria
- Industrial yeast strains
- Filamentous fungi
- Non-model microorganisms
We can help develop a solution that fits your project, whether you need precise genome editing in an established production strain or a difficult-to-engineer microorganism.
Remove undesired cells with precision
BEC® (BRAIN Engineered Cas) nucleases enable a unique approach to cell population control. These nucleases remain inactive until triggered by a programmable signal. Once activated, they selectively eliminate cells carrying unwanted characteristics, enabling targeted cell depletion within heterogeneous populations. This unique mechanism was recently described by Scholz et al. (2026, Nature)*. BEC® technology can support applications such as:
- Depleting phage- or virus-infected cells during bioprocessing
- Eliminating pest-infested plant seedlings
- Accelerating the modification of difficult-to-engineer microorganisms
- Commercial users can license our patented BEC® technology (EP 4 025 691 B1) through flexible licensing agreements.
* Scholz, P., Thompson, J., Crosby, K.T. et al. RNA-triggered cell killing with CRISPR-Cas12a2. Nature (2026). https://doi.org/10.1038/s41586-026-10466-y
Note: BMC® and BEC® are EU word marks of BRAIN Biotech AG
